Study of XL281 in Adults With Solid Tumors
Completed · Phase 1
Conditions studied: Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma
In brief
The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
Key facts
- Study ID
- NCT00451880
- Run by
- Exelixis
- People needed
- 180
- Starts
- 2007-02-01
- Expected to finish
- 2011-10-01
- Last updated by the study team
- 2011-10-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Premiere Oncology of Arizona — Scottsdale, Arizona, United States
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Mary Crowley Cancer Research Center — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.